Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.
The Preference and Satisfaction Questionnaire (PSQ) compares patient preference and satisfaction between a 6-month subcutaneous injection and weekly oral tablet for treatment of bone loss. Patients preferred and were more satisfied with a treatment that was administered less frequently, suggesting the acceptability of the 6-month injection for treatment of bone loss.


BACKGROUND
The PSQ compares patient preference and satisfaction between a 6-month subcutaneous injection and a weekly oral tablet for treatment of bone loss.


METHODS
Postmenopausal women with low bone mass who enrolled in two separate randomized phase 3 double-blind, double-dummy studies received a 6-month subcutaneous denosumab injection (60 mg) plus a weekly oral placebo or a weekly alendronate tablet (70 mg) plus a 6-month subcutaneous placebo injection. After 12 months, patients completed the PSQ to rate their preference, satisfaction, and degree of bother with each regimen.


RESULTS
Most enrolled patients (1,583 out of 1,693; 93.5%) answered >or=1 item of the PSQ. Significantly more patients preferred and were more satisfied with the 6-month injection versus the weekly tablet (P < 0.001). More patients reported no bother with the 6-month injection (90%) than the weekly tablet (62%).


CONCLUSIONS
Patients preferred, were more satisfied, and less bothered with a 6-month injection regimen for osteoporosis.
Kendler
D L
DL
Prohealth Clinical Research, University of British Columbia, Vancouver, BC, Canada. kendler@ca.inter.net
Bessette
L
L
Hill
C D
CD
Gold
D T
DT
Horne
R
R
Varon
S F
SF
Borenstein
J
J
Wang
H
H
Man
H-S
HS
Wagman
R B
RB
Siddhanti
S
S
Macarios
D
D
Bone
H G
HG
D000284:Administration, Oral; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D000069448:Denosumab; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D057240:Patient Preference; D017060:Patient Satisfaction; D011594:Psychometrics; D053245:RANK Ligand / Q000008:administration & dosage; D013607:Tablets
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D013607:Tablets; D000069448:Denosumab; D019386:Alendronate